Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04918186 | Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | PHASE2 | RECRUITING | 60 | — | — | May 3, 2022 | Dec 31, 2026 | May 12, 2026 | 7 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Durvalumab + BA3011 (Arm Closed) | EXPERIMENTAL | - |
| Durvalumab + BA3021 (Arm Closed) | EXPERIMENTAL | - |
| ENB-003 + Toripalimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Durvalumab | DRUG | 1500mg IV, 60 min day 1 every 4 weeks |
| BA3011 | DRUG | IV |
| BA3021 | DRUG | IV |
| ENB003 | DRUG | IV |
| Toripalimab | DRUG | IV |
Inclusion Criteria: * This study will enroll women with platinum resistant high grade serous ovarian cancer. * This study is open to minorities as appropriate but is not designed to measure differences in intervention effects. * All patients must be registered for screening prior to study enrollmen...